Cowen and Company Reiterates Outperform Rating for Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Cornelia Mascio
Settembre 24, 2017

They now have a Dollars 15 price target on the stock. Leerink Swann maintained the stock with "Buy" rating in Monday, August 31 report. The firm earned "Buy" rating on Tuesday, August 18 by Zacks. The consensus rating is 1.5, indicating analysts in general look favorably on the company's future prospects. The rating was maintained by Cowen & Co on Monday, August 7 with "Buy". Goldman Sachs Group Inc. lifted its holdings in shares of Amicus Therapeutics by 5.7% during the first quarter.

Not surprisingly, $14.72 is the stock's new 52 week high. The 9 months bullish chart indicates low risk for the $2.41B company. They now have a United States dollars 16.5 price target on the stock. About 1.31M shares traded. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since September 19, 2016 and is uptrending. It has underperformed by 4.25% the S&P500. It has underperformed by 9.34% the S&P500. The company's market cap is $2.30 billion. The Firm operates in approximately 30 markets. Now has a PEG ratio of - where as its P/E ratio is 2.48. The Company's divisions include Distribution, Retail and Central. Bank Of America Corp De has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 168,709 shares. (NASDAQ:ARII) to report $0.55 EPS on October, 27.They anticipate $0.39 EPS change or 41.49% from last quarter's $0.94 EPS. Therefore 89% are positive. (NASDAQ:FOLD) for 55,411 shares. On Tuesday, January 24 the stock rating was upgraded by Robert W. Baird to "Outperform". Moreover, Nationwide Fund Advisors has 0.01% invested in Amicus Therapeutics, Inc.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Monday, August 7th. About 4.27M shares traded or 18.61% up from the average. The stock has "Outperform" rating by Robert W. Baird on Wednesday, July 12. JP Morgan has "Overweight" rating and $49 target. The legal version of this piece can be viewed at (NASDAQ:FOLD) to report earnings on November, 6. The rating was maintained by Cowen & Co with "Buy" on Sunday, August 13. (NASDAQ:FOLD) has "Neutral" rating given on Thursday, April 14 by Robert W. Baird.

Investors sentiment increased to 1.23 in Q2 2017. Its down 0.25, from 1.49 in 2016Q3. Amicus Therapeutics, Inc. earnings have declined with an annualized rate of -3% over the last 5 years. 25 funds opened positions while 48 raised stakes. California Public Employees Retirement Systems reported 176,800 shares. Quantitative Systematic Strategies Limited Liability owns 10,977 shares or 0.03% of their U.S. portfolio.

Janus Cap Mgmt Ltd Liability Corp holds 0.03% of its portfolio in Amicus Therapeutics, Inc.

Large investors have recently made changes to their positions in the company. Paloma Prns Management Com invested in 13,100 shares. Comml Bank Of Nova Scotia owns 193,050 shares. 26,396 were reported by Principal Fin Gp Incorporated Inc. The Manitoba - Canada-based Great West Life Assurance Can has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 3.04M shares. Finally, Cowen and Company reiterated an outperform rating and issued a $18.00 price objective (up previously from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, September 14th. Royal Bancorp Of Canada holds 0% or 11,396 shares. Axa has invested 0.05% in Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 418,730 shares. (NASDAQ:FOLD). Illinois-based Citadel Advisors has invested 0.02% in Amicus Therapeutics, Inc. The last session's volume was 3,046,076 compared to its average daily volume of 470.38K shares. That gives us a street projected return of 10.02%. Proshare Advisors Limited Liability Com accumulated 86,041 shares. Insiders own 3.40% of the company's stock. Do Hung had sold 29,914 shares worth $239,312 on Friday, May 19. Wells Fargo & Company MN boosted its stake in Amicus Therapeutics by 51.7% in the first quarter.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE